{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:52:56Z","timestamp":1787014376044,"version":"build-2736575974"},"reference-count":70,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T00:00:00Z","timestamp":1644105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Palmoplantar pustulosis (PPP) and palmoplantar pustular psoriasis (PPPP) are chronic inflammatory skin conditions characterized by eruptions of sterile pustules on the palms and\/or soles. Biologic use has been associated with PPP and PPPP development in the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To identify PPP and PPPP associated with biologics and summarize reported treatments and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched in MEDLINE and Embase for articles that reported PPP or PPPP during biologic treatment. After a full\u2010text review, 53 studies were included for analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 155 patients with PPP\/PPPP onset during biologic treatment, with a mean age of 44.1\u2009years and a female preponderance (71.6%). The most frequently reported biologics were adalimumab (43.9%) and infliximab (33.3%). IL\u201017 inhibitors, secukinumab (7.6%) and brodalumab (1.5%), were reported only in association with PPPP. Overall, 58.8% of patients had complete remission (CR) in 3.6\u2009months and 23.5% had partial remission (PR) in 3.7\u2009months. The most common treatments that led to CR were topical corticosteroids (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916) and biologic switching (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinicians should anticipate PPP or PPPP as potential drug reactions to biologics such as adalimumab and infliximab. Large\u2010scale studies are required to confirm our findings and further explore the pathogenesis for biologic\u2010associated PPP and PPPP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ijd.16064","type":"journal-article","created":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T22:43:58Z","timestamp":1644187438000},"page":"12-21","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Biologic therapies associated with development of palmoplantar pustulosis and palmoplantar pustular psoriasis: a systematic review"],"prefix":"10.1111","volume":"62","author":[{"given":"Justin D.","family":"Lu","sequence":"first","affiliation":[{"name":"Faculty of Medicine Michael G. DeGroote School of Medicine  Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Lytvyn","sequence":"additional","affiliation":[{"name":"Faculty of Medicine University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asfandyar","family":"Mufti","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Zaaroura","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2252-5663","authenticated-orcid":false,"given":"Muskaan","family":"Sachdeva","sequence":"additional","affiliation":[{"name":"Faculty of Medicine University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kwan","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abrahim","family":"Abduelmula","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Schulich School of Medicine and Dentistry  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9933-8487","authenticated-orcid":false,"given":"Patrick","family":"Kim","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Michael G. DeGroote School of Medicine  Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jensen","family":"Yeung","sequence":"additional","affiliation":[{"name":"Faculty of Medicine University of Toronto  Toronto Ontario Canada"},{"name":"Department of Dermatology University of Toronto  Toronto Ontario Canada"},{"name":"Sunnybrook Health Sciences Centre  Toronto Ontario Canada"},{"name":"Women's College Hospital  Toronto Ontario Canada"},{"name":"Probity Medical Research Inc.  Waterloo Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12223"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.11.910"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2016.09.019"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546631003636817"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.186"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2020.03.003"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.05.029"},{"key":"e_1_2_7_10_1","first-page":"1136","article-title":"Adalimumab in the management of palmoplantar psoriasis","volume":"8","author":"Ghate JV","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0207-0"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.082842"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02335.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2007.06.011"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181d59511"},{"key":"e_1_2_7_17_1","first-page":"269","article-title":"New\u2010onset palmoplantar psoriasis during treatment of active ankylosing spondylitis with TNF\u2010alpha blocking agent adalimumab","volume":"26","author":"Akgul O","year":"2011","journal-title":"Arch Rheumato"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.275"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.10.007"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-2265-4"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2012.06.010"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2012.05707.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2016.28.4.522"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.06.003"},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","unstructured":"BaeJM LeeHH.Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population\u2010based cohort study.2018;48:196\u2013205.","DOI":"10.1111\/apt.14822"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2018.200"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.12.006"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200809010-00001"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02898.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09329.x"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546630902882089"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000345468"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000339864"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120304"},{"key":"e_1_2_7_35_1","first-page":"16","article-title":"Palmoplantar pustulosis with fulminant dystrophic 20\u2010nail psoriasis in a patient receiving adalimumab therapy","volume":"12","author":"Mishra V","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13033"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.9.829"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06977.x"},{"key":"e_1_2_7_39_1","first-page":"380","article-title":"Psoriasis induced by tumor necrosis factor\u2010alpha antagonist therapy: a case series","volume":"34","author":"Cohen JD","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"e_1_2_7_40_1","first-page":"434","article-title":"New\u2010onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect?","volume":"34","author":"Roux CH","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-008-0831-8"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/039463200902200331"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.08.009"},{"key":"e_1_2_7_44_1","first-page":"1","article-title":"Beh\u00e7et's syndrome treated with infliximab, which caused a palmoplantar pustulosis, subsequently maintained on low\u2010dose etanercept. Libyan","volume":"7","author":"Tresh A","year":"2012","journal-title":"J\u00a0Med"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.11.1449-a"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e318228bcb6"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2010.521811"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-011-8262-2"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2012.01894.x"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsi.2017.04.008"},{"key":"e_1_2_7_51_1","first-page":"40","article-title":"A case of palmoplantar pustulosis induced by certolizumab pegol: new anti\u2010TNF\u2010alpha demonstrates the same class effect","volume":"5","author":"Shelling ML","year":"2012","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_7_52_1","doi-asserted-by":"crossref","unstructured":"GawdzikA PonikowskaM Jankowska\u2010KonsurA et\u2009al.Paradoxical skin reaction to certolizumab an overlap of pyoderma gangrenosum and psoriasis in a young woman treated for ankylosing spondylitis: case report with literature review.2020;10:869\u2013879.","DOI":"10.1007\/s13555-020-00398-4"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13530"},{"key":"e_1_2_7_54_1","doi-asserted-by":"crossref","unstructured":"Ferri\u00e8resL KonstantinouMP BulaiLC.Long\u2010term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance.2019;44:e230\u2010e4.","DOI":"10.1111\/ced.13999"},{"key":"e_1_2_7_55_1","doi-asserted-by":"crossref","unstructured":"HonmaM NozakiH.Palmoplantar pustulosis emerged on a case of generalized pustular psoriasis successfully treated by secukinumab.2019;46:e468\u2010e9.","DOI":"10.1111\/1346-8138.15082"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2020.3702"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15714"},{"key":"e_1_2_7_58_1","doi-asserted-by":"crossref","unstructured":"BenzaquenM FlachaireB.Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn's disease\u2010associated spondyloarthropathy.2018;38:1297\u20131299.","DOI":"10.1007\/s00296-018-4034-0"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1159\/000362266"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.03.024"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180566"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04866.x"},{"key":"e_1_2_7_63_1","first-page":"700","article-title":"Anti\u2010tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?","volume":"30","author":"Joyau C","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.12.018"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02746"},{"key":"e_1_2_7_66_1","doi-asserted-by":"crossref","unstructured":"ConradC Di DomizioJ.TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis.2018;9:25.","DOI":"10.1038\/s41467-017-02466-4"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1086\/503821"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630802441234"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.05.044"},{"key":"e_1_2_7_70_1","first-page":"139","article-title":"Remicade(\u00ae) (infliximab): 20 years of contributions to science and medicine","volume":"13","author":"Melsheimer R","year":"2019","journal-title":"Biologics"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-015-0162-4"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.16064","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.16064","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.16064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T21:31:42Z","timestamp":1692567102000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.16064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,6]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/ijd.16064"],"URL":"https:\/\/doi.org\/10.1111\/ijd.16064","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,6]]},"assertion":[{"value":"2021-08-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}